News
SVA
6.47
0.00%
0.00
Market Chatter: BioNTech COVID-19 Vaccines Shipped to China From Germany
Market Chatter: BioNTech COVID-19 Vaccines Shipped to China From Germany
MT Newswires · 12/21/2022 10:14
Germany to allow Sinovac vaccine for Chinese citizens only - Spiegel
Reuters · 12/07/2022 14:15
BRIEF-Oci International Says Investment Fund Was Set Up
Reuters · 11/24/2022 11:19
Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It
Benzinga · 11/22/2022 19:45
Chinese and Indonesian presidents pledge more COVID vaccine cooperation
Reuters · 11/16/2022 20:17
Sinovac Biotech Says World Health Organization Approved Varicella Vaccine
Sinovac Biotech Says World Health Organization Approved Varicella Vaccine
MT Newswires · 11/04/2022 05:25
Reported Late Thursday, Sinovac Biotech's Varicella Vaccine Prequalified By WHO
Benzinga · 11/04/2022 04:58
BRIEF-Sinovac Biotech Says Varicella Vaccine Prequalified By WHO
Reuters · 11/04/2022 02:04
SINOVAC Varicella Vaccine Prequalified by WHO
BEIJING, November 04, 2022--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization (WHO) for its live ...
Business Wire · 11/04/2022 02:03
SINOVAC to Showcase Products at CPHI Frankfurt
BEIJING, October 28, 2022--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the world’s largest pharmaceutical ...
Business Wire · 10/28/2022 09:00
Indonesia approves first home-grown COVID vaccine for emergency use - media
Indonesia approves first home-grown COVID vaccine for emergency use - media
Reuters · 09/28/2022 09:16
SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud
Benzinga · 09/06/2022 10:01
Sinovac Biotech Gets Chilean Health Regulator Approval to Start Clinical Trial for Its Omicron Containing COVID-19 Vaccine
Sinovac Biotech Gets Chilean Health Regulator Approval to Start Clinical Trial for Its Omicron Containing COVID-19 Vaccine
MT Newswires · 09/06/2022 06:33
UPDATE 1-China approves Livzon Pharma's COVID vaccine, among first new products in more than a year
UPDATE 1-China approves Livzon Pharma's COVID vaccine, among first new products in more than a year
Reuters · 09/02/2022 14:00
China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
Reuters · 08/29/2022 01:02
Sinovac's COVID shot approved for use in children aged 6 months to 3 years in Hong Kong
Sinovac Biotech (NASDAQ:SVA) on Wednesday said its COVID-19 v...
Seekingalpha · 08/03/2022 14:31
SINOVAC COVID-19 Vaccine Approved For Use In Children Above 6 months Of Age in Hong Kong
Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination
Benzinga · 08/03/2022 10:06
HK Experts Back Covid Shots Starting at Six Months of Age
Bloomberg · 08/01/2022 12:00
Sinovac begins late-stage trial of influenza vaccine in Chile
Sinovac Biotech (NASDAQ:SVA) <a href="https://seekingalpha.co...
Seekingalpha · 07/19/2022 16:27
BRIEF-Sinovac Initiates Clinical Trial For Its Quadrivalent Influenza Vaccine In Chile
BRIEF-Sinovac Initiates Clinical Trial For Its Quadrivalent Influenza Vaccine In Chile
Reuters · 07/19/2022 05:32
More
Webull provides a variety of real-time SVA stock news. You can receive the latest news about Sinovac Biotech Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SVA
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.